Article Text

Download PDFPDF

P095 Plasma levels of HSP90 are increased in patients with systemic sclerosis with more severe organ involvement
  1. H Storkanova1,2,
  2. S Oreska1,2,
  3. M Spiritovic2,3,
  4. K Pavelka1,2,
  5. J Vencovský1,2,
  6. J Distler4,
  7. L Senolt1,2,
  8. R Becvar1,2,
  9. M Tomcik1,2
  1. 1Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
  2. 2Institute of Rheumatology, Prague, Czech Republic
  3. 3Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic
  4. 4Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany


Introduction Our previous study demonstrated that Hsp90 is overexpressed in the skin of patients with systemic sclerosis (SSc), in cultured SSc fibroblasts and preclinical models of SSc. We showed that Hsp90 is a regulator of TGF-β signalling and its inhibition prevents the stimulatory effects of TGF-β on collagen synthesis and dermal fibrosis in three preclinical models of SSc.1

Objectives The aim of this study was to evaluate Hsp90 in the circulation of SSc patients and characterise its potential association with skin changes and SSc-related features.

Methods A total of 91 patients (78 females; mean age 52.7; disease duration 6.0 years; diffuse cutaneous (dc)SSc/limited cutaneous (lc)SSc=38/53) who met the ACR/EULAR 2013 criteria for SSc and 85 age-/sex- matched healthy controls (HC) were included. Plasma Hsp90 was measured by ELISA. Data are presented as median (IQR).

Results Plasma Hsp90 levels were increased in SSc patients compared to HC [12.5 (9.6–17.9) vs. 9.9 (7.9–12.6) ng/mL, p=0.001], but no difference between lcSSc and dcSSc were detected [13.1 (9.4–18.1) vs. 11.5 (9.5–17.5) ng/mL, p=0.316]. Hsp90 levels in all patients positively correlated with CRP (r=0.313, p=0.006). Furthermore, Hsp90 was increased in patients with interstitial lung disease (ILD) compared to those without ILD [12.8 (10.2–17.9) vs. 10.3 (8.6–16.6) ng/mL, p=0.045] and was negatively associated with functional parameters of ILD: FVC (=−0.299, p=0.011), FEV1 (r=−0.256, p=0.031), DLCO (r=−0.303, p=0.009) and SpO2 (r=−0.317, p=0.038). In addition, only in patients with dcSSc, Hsp90 levels positively correlated with the mRSS (r=0.437, p=0.006). Hsp90 concentrations were not significantly affected by other main clinical parameters of SSc.

Conclusions We demonstrated higher plasma levels of Hsp90 in SSc patients compared to healthy controls. Concentrations of extracellular Hsp90 increase with higher inflammatory activity, with deteriorated lung functions in ILD and also with the extent and severity of the skin involvement in patients with diffuse cutaneous SSc. These data further highlight the role of Hsp90 as a significant regulator of fibroblast activation and tissue fibrosis in SSc.


  1. . Tomcik M, et al. Ann Rheum Dis2014;73(6):1215–22.

Acknowledgements Supported by AZV – 16–33542A and SVV – 2 60 373.

Disclosure of interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.